Affiliations: [a] HyClone Laboratories, Logan, Utah, USA | [b] ADVS Department, Utah State University, Logan, Utah, USA | [c] HYGEIA Pharmaceuticals, San Diego, CA, USA
Note: [] Address reprint requests to Dr. Anthony R. Torres, HyClone Laboratories Inc., 1725 S. HyClone Rd., Logan, UT 84321, USA.
Abstract: An agamma calf serum (ACS) was compared to fetal bovine serum (FBS) and calf serum supplemented growth media for both murine and human fusion partners and derived hybridoma cells. The variables analyzed were cloning efficiencies, growth characteristics, and MAb production levels. Cultures were established in each serum source, and supernatants were kept for analysis. For cloning efficiencies, the results indicate that although there is no clear advantage in the performance of FBS-supplemented medium, ACS-supplemented RPMI 1640 medium can be used to clone hybridomas and the fusion partners. When analyzed for MAb production in the various sera, the hybridoma cell lines used in this study appeared to produce up to twice as much immunoglobulin when grown in ACS as when grown in supplemented medium. IgG- and IgM-secreting hybridoma cultures should be checked independently for antibody production. Six out of eight murine and human hybridoma cell lines produced higher levels of MAbs when grown in ACS.
